Scholar Rock Holding Corporation (NASDAQ:SRRK) Receives Consensus Rating of “Buy” from Analysts

Scholar Rock Holding Corporation (NASDAQ:SRRK) has been assigned a consensus recommendation of “Buy” from the seventeen brokerages that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, twelve have issued a buy rating and four have issued a strong buy rating on the company. The average 12-month price target among analysts that have covered the stock in the last year is $51.1429.

A number of equities analysts recently commented on the company. Barclays raised their target price on Scholar Rock from $45.00 to $52.00 and gave the company an “overweight” rating in a report on Wednesday, December 17th. Wolfe Research started coverage on shares of Scholar Rock in a research note on Tuesday, November 18th. They set an “outperform” rating and a $42.00 target price on the stock. HC Wainwright raised their price target on shares of Scholar Rock from $44.00 to $58.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Cantor Fitzgerald restated an “overweight” rating on shares of Scholar Rock in a research note on Thursday, December 11th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Scholar Rock in a research report on Thursday, January 22nd.

Scholar Rock Stock Performance

NASDAQ:SRRK opened at $44.34 on Friday. Scholar Rock has a fifty-two week low of $22.71 and a fifty-two week high of $48.28. The company has a debt-to-equity ratio of 0.41, a quick ratio of 6.30 and a current ratio of 6.30. The company has a 50 day moving average price of $44.27 and a 200 day moving average price of $37.54. The stock has a market capitalization of $4.52 billion, a P/E ratio of -14.08 and a beta of 0.63.

Scholar Rock (NASDAQ:SRRK) last released its quarterly earnings results on Friday, November 14th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.02). During the same period in the prior year, the business posted ($0.66) earnings per share. Equities research analysts forecast that Scholar Rock will post -2.42 EPS for the current year.

Insider Buying and Selling

In other news, General Counsel Junlin Ho sold 8,016 shares of Scholar Rock stock in a transaction dated Friday, January 16th. The stock was sold at an average price of $44.48, for a total value of $356,551.68. Following the completion of the transaction, the general counsel owned 214,553 shares in the company, valued at approximately $9,543,317.44. This trade represents a 3.60% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO David Hallal sold 57,450 shares of the business’s stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $42.70, for a total value of $2,453,115.00. Following the transaction, the chief executive officer directly owned 1,541,645 shares of the company’s stock, valued at approximately $65,828,241.50. This represents a 3.59% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 305,687 shares of company stock worth $13,540,573 over the last ninety days. Company insiders own 13.30% of the company’s stock.

Institutional Investors Weigh In On Scholar Rock

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Moody Aldrich Partners LLC raised its stake in Scholar Rock by 53.5% during the 3rd quarter. Moody Aldrich Partners LLC now owns 101,742 shares of the company’s stock worth $3,789,000 after acquiring an additional 35,481 shares in the last quarter. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. grew its holdings in shares of Scholar Rock by 145.3% during the second quarter. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. now owns 769,442 shares of the company’s stock worth $27,254,000 after purchasing an additional 455,753 shares during the last quarter. Norges Bank acquired a new stake in shares of Scholar Rock during the second quarter worth about $41,628,000. Voya Investment Management LLC lifted its holdings in shares of Scholar Rock by 18.1% in the 3rd quarter. Voya Investment Management LLC now owns 443,155 shares of the company’s stock valued at $16,503,000 after purchasing an additional 67,839 shares during the last quarter. Finally, Ensign Peak Advisors Inc boosted its position in shares of Scholar Rock by 78.8% in the 2nd quarter. Ensign Peak Advisors Inc now owns 600,639 shares of the company’s stock valued at $21,275,000 after purchasing an additional 264,693 shares during the period. 91.08% of the stock is currently owned by institutional investors and hedge funds.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).